retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity (GLP-3): The Peptide — Research Overview – Emerald Peptides Weight loss with retatrutide as

This is supported by the companys focus on expanding its MC4R franchise into adjacent areas, such as acquired hypothalamic obesity to drive growth [59]

Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking RYBELSUS Adverse Reactions Most common adverse reactions (incidence 5%) are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation Drug Interactions RYBELSUS stimulates insulin release in the presence of elevated blood glucose concentrations

Safety Profile and Side Effects of GLP-1 Drugs Whilst GLP-1 receptor agonists are generally well-tolerated, healthcare professionals and patients must be aware of their safety profile to ensure appropriate use and monitoring

Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss